Pilot study identifies key vulnerabilities in anesthetic and psychotropic drug management, suggesting FMEA enhances safety.
In China, anesthetic drugs and class I psychotropic drugs are among the most stringently managed special medications within medical institutions. In this study, we aimed to use Failure Mode and Effects Analysis (FMEA) to conduct a proactive risk assessment of management models for these drugs, addressing their unique management requirements. We established a multidisciplinary team and identified five main stages of the process. Each stage was divided into micro-activities to identify potential failure modes and their possible consequences. A risk priority number for each failure mode was calculated. The management of anesthetic drugs and class I psychotropic drugs in inpatient pharmacy revealed 15 types of failure modes, with Risk Priority Numbers (RPN) ranging from 4.21 to 38.09. The very high-/high-priority errors identified included two key categories with specific quantitative risks: (1) Patients' inability to receive medications in a timely manner (2) Discrepancies between empty ampule collection and dispensing quantities. The latter category posed significant management risks, as evidenced by RPN values exceeding 30, which indicated a high likelihood of regulatory non-compliance and increased circulation vulnerabilities. FMEA proved effective in identifying key vulnerabilities in the management of anesthetic and Class I psychotropic drugs. These findings can guide the development of a targeted information management system that will leverage modern digital tools to improve drug compliance and patient safety.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: